(NASDAQ: EQ) Equillium's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.78%.
Equillium's earnings in 2026 is -$18,009,000.On average, 13 Wall Street analysts forecast EQ's earnings for 2026 to be -$13,391,787, with the lowest EQ earnings forecast at -$13,670,782, and the highest EQ earnings forecast at -$11,318,343. On average, 13 Wall Street analysts forecast EQ's earnings for 2027 to be -$14,957,967, with the lowest EQ earnings forecast at -$22,370,371, and the highest EQ earnings forecast at -$8,655,203.
In 2028, EQ is forecast to generate -$17,798,649 in earnings, with the lowest earnings forecast at -$22,991,771 and the highest earnings forecast at -$12,649,912.